Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 18 12 2018
accepted: 23 01 2019
pubmed: 9 2 2019
medline: 15 5 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

There are conflicting reports for the outcome of the patients with giant cell tumor of bone (GCTB) and pathological fracture at presentation treated with curettage or resection. This study compared local recurrence, complications, and function after curettage versus resection for these patients. We retrospectively studied the files of 46 patients with histologically confirmed GCTB of the extremities admitted and treated from 1982 to 2015. The median follow-up was 79.5 months (57.0-125.5 months). We evaluated local recurrence and type of surgery-related complications with imaging and function with the Musculoskeletal Tumor Society (MSTS) score. Overall local recurrence was 6.5%. There were one patient with curettage and two patients with resection; local recurrence rate was similar between the two procedures but the time to local recurrence was shorter after curettage. MSTS score was significantly better after curettage. Complications occurred in two patients after curettage and in five patients after resection; because of the low number of patients with complications, a statistical comparison was not possible; however, by direct comparison of the numbers, complications were more common after resection compared with curettage. Curettage is recommended for GCTB and pathological fracture at presentation because of similar local recurrence but better function compared with resection. The treating physicians should be aware and inform their patients for a shorter time to local recurrence after curettage and for more complications after resection.

Sections du résumé

BACKGROUND BACKGROUND
There are conflicting reports for the outcome of the patients with giant cell tumor of bone (GCTB) and pathological fracture at presentation treated with curettage or resection. This study compared local recurrence, complications, and function after curettage versus resection for these patients.
MATERIALS AND METHODS METHODS
We retrospectively studied the files of 46 patients with histologically confirmed GCTB of the extremities admitted and treated from 1982 to 2015. The median follow-up was 79.5 months (57.0-125.5 months). We evaluated local recurrence and type of surgery-related complications with imaging and function with the Musculoskeletal Tumor Society (MSTS) score.
RESULTS RESULTS
Overall local recurrence was 6.5%. There were one patient with curettage and two patients with resection; local recurrence rate was similar between the two procedures but the time to local recurrence was shorter after curettage. MSTS score was significantly better after curettage. Complications occurred in two patients after curettage and in five patients after resection; because of the low number of patients with complications, a statistical comparison was not possible; however, by direct comparison of the numbers, complications were more common after resection compared with curettage.
CONCLUSION CONCLUSIONS
Curettage is recommended for GCTB and pathological fracture at presentation because of similar local recurrence but better function compared with resection. The treating physicians should be aware and inform their patients for a shorter time to local recurrence after curettage and for more complications after resection.

Identifiants

pubmed: 30734307
doi: 10.1002/jso.25391
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

864-872

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Shinji Tsukamoto (S)

Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara, Japan.

Andreas F Mavrogenis (AF)

First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Piergiuseppe Tanzi (P)

Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Giulio Leone (G)

Department of Orthopaedic Surgery, San Gerardo Hospital, Monza, Italy.

Alberto Righi (A)

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Manabu Akahane (M)

Department of Public Health, Health Management and Policy, Nara Medical University, Kashihara, Nara, Japan.

Akira Kido (A)

Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara, Japan.

Kanya Honoki (K)

Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara, Japan.

Yasuhito Tanaka (Y)

Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara, Japan.

Davide Maria Donati (DM)

Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Costantino Errani (C)

Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH